Member access

4-Traders Homepage  >  Shares  >  Xetra (Allemagne)  >  Novartis AG    NOT   CH0012005267

NOVARTIS AG

 (NOT)
2
 SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisionsForum 
Quotes 5-day view   End-of-day quote. End-of-day quote Xetra (Allemagne)
05/13/2013 05/14/2013 05/15/2013 05/16/2013 05/17/2013 Date
57.61(c) 57.46(c) 58.7(c) 58.4(c) 57.46(c) Last
23 773 17 414 17 523 22 221 24 388 Volume
-0.12% -0.26% +2.16% -0.51% -1.61% Change
More quotes
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (55.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Read more
Surperformance© rating of Novartis AG
Trading Rating : Investor Rating :
More about the company
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOT | CH0012005267 | 4-Traders
Full-screen chart
Financials ($)
Sales 2013 57 379 M
EBIT 2013 13 464 M
Net income 2013 9 599 M
Debt 2013 7 067 M
Yield 2013 3,36%
Sales 2014 59 416 M
EBIT 2014 14 627 M
Net income 2014 11 141 M
Debt 2014 2 320 M
Yield 2014 3,58%
PER 2013 17,00
PER 2014 15,50
EV / Sales 2013 3,63x
EV / Sales 2014 3,43x
Capitalization 201 295 M
More Financials
Latest news on NOVARTIS AG
1d ago NOVARTIS AG: Novartis drug Afinitor® significantly extended time without diseas..
1d ago NOVARTIS AG: drug Afinitor® significantly extended time without disease progres..
1d ago NOVARTIS AG: Novartis wins GBCHealth Business Action on Health Award for social..
1d ago NOVARTIS AG: wins GBCHealth Business Action on Health Award for social ventures..
3d agoDJNovartis Considers Possible Bid for Actavis
05/10DJNOVARTIS AG: Correction to Story on Novartis's FDA Approval for Ilaris
05/10 Drugmakers face more scrutiny of discordant U.S. prices
05/10DJNOVARTIS AG: Novartis : FDA Approves Ilaris for Serious Form of Childhood Arthr..
05/10 NOVARTIS AG: Novartis drug Ilaris® approved by FDA to treat active systemic juv..
05/10 NOVARTIS AG: drug Ilaris® approved by FDA to treat active systemic juvenile idi..
05/09 Merck sales representative claims sexual bias, seeks over $100 million
05/08 NOVARTIS AG: Real-world data at ARVO highlight transformational outcomes seen w..
More news
Forum NOVARTIS AG
Be the first to post a message on NOVARTIS AG
Advertisement
Income Statement Evolution
Novartis AG : Income Statement Evolution
More Financials
EPS Revisions
Novartis AG : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF
My Watchlist|My Portfolio
4-traders.com :
About :
Copyright © 2013 Surperformance. All rights reserved.